In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts [see comments]
BR Blazar(University of Minnesota Medical Center), NK Ramsay(University of Minnesota Medical Center), C Epstein(University of Minnesota Medical Center), LC Lasky(University of Minnesota Medical Center), DR Weisdorf(Palmetto Hematology Oncology), PB McGlave(University of Minnesota Medical Center), R Haake(University of Minnesota), JH Kersey(University of Minnesota Medical Center), DA Vallera(University of Minnesota Medical Center), Bruce Bostrom(Minnesota West Community & Technical College)
Cited by 1
Related Papers
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
|Journal of Clinical Oncology|2009|278